

HLA-DR

Product: Anti-human B and T subset Lymphocyte Monoclonal Antibody.


Description: Identification of human B cell and T cell subsets associated with approximately 10% of peripheral blood lymphocytes 28-34,000 M.W. surface antigen, also low density on monocytes and macrophages.

Isotype: Mouse IgG-2A kappa.

Clone: 423L

Applications: Monitoring of B cells in peripheral blood; Analysis of B subsets; Study of B cell activation; Study of B cell neoplasms.

Use: PBMC: Add 10 μ l of MAB/10⁶ PBMC in 100 μ l PBS. Mix gently and incubate for 15 minutes at 2^o to 8^oC. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add 10 μ l of MAB/100 μ l of whole blood. Mix gently and incubate for 15 minutes at room temperature 20^oC. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer's instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.



Storage: Unconjugated antibodies supplied as a 1 mg/ml solution PBS and 0.08% sodium azide and should be stored at -20^oC. Conjugated antibodies are supplied in PBS, 0.08% sodium azide and 0.2% protein carrier and should be stored at 4-8^oC. Conjugated antibodies should not be frozen. Reagents are stable for the period shown on the vial label when stored properly.

Ordering Information:	Form	Vial Size	Catalog #
	Pure*	100 μ g	0DR1
	FITC	100 Test	0DR2
	Biotin	100 Test	0DR3
	PE	100 Test	0DR4

* Pure form tested for Exalpa for cross-reactivity with *Macaca* species monkey.

For research use only. Not for use in human diagnostics or therapeutics.

REFERENCES:

1. IL-4 and granulocyte-macrophage colony-stimulating factor selectively increase HLA-DR and HLA-DP antigens but not HLA-DQ antigens on human monocytes. Gerrard T.L., Dyer D.R., Mostowski H.S., J. Immunol. 1990 June, 1;144(12): 4670-4.
2. Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules. Karp D.R., Teletski C.L., Jaraquemada D., Maloy W.L., Coligan J.E., Long E.O., J. Exp. Med. 1990 March ;171(3):615-28.
3. Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Hu K.Q., Vierling J.M., Siddiqui A., Proc. Natl. Acad. Sci. USA 1990 SEPT.; 87(18):7140-4.
4. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. Verfaillie C., Blakolmer K., McGlave P., J. Exp. Med. 1990 Aug.: 172(2):509-2.
5. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+ CD8+ DR+ CD25- T cell population. Pantaleo G., Keonig S., Baseler M., Lane H.C., Fauci A.S., J. Immunol. 1990 Mar ; 144(5):1696-704.
6. Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy. Raziuddin S., Nur M.A., al-Wabel A.A., Scand. J. Immunol. 1990 Feb.:31(2):139-45.

For research use only. Not for use in human diagnostics or therapeutics.

Exalpa Biologicals, Inc., 86 Rosedale Rd. Watertown, MA 02472
Tel: 800.395.1137 or 617.924.3400, Fax: 866.924.5100 or 617.924.5100, Web:www.exalpa.com